BIO-Europe in the Press
Featured coverage from leading global business, healthcare and biotech publications
BIO-Europe: Why meeting Matters
In a world where we can connect with potential partners at the touch of a button, do face-to-face meetings still matter?
As deals grow larger and decision-making becomes more complex – trust, alignment and meaningful connections are more valuable than ever.
“Face-to-face meetings have never been more important, and I think they are only going to become more so,” Claire Macht, Informa Connect, tells Optimum TV. “People want to share experiences, gain insight from the outside of their bubble. And this is the key path to building cross-functional alignment and growth direction."
In the episode, Claire discusses how BIO-Europe is evolving to meet the changing needs of biotech and pharma, and why neutral forums remain essential spaces for open, honest industry conversations.
Articles
Pharmalittle: We're reading about WHO obesity guidelines for kids, DOJ targeting pharma, and more
More than half of the executives of biotech companies say that U.S. policy and regulatory uncertainty has made Europe more attractive as a place to build and partner, according to a survey by the BIO-Europe conference group.
Report: Europe’s biotech leaders see recovery, but investors remain the obstacle
Exclusive European data from BIO-Europe’s inaugural C-suite survey, shared with European Biotechnology, shows a sector expecting better funding conditions while struggling with investor caution.
ADCs evolve from niche therapy to cancer cornerstone
Ona Therapeutics' Valerie Vanhooren discusses how innovative biology, advanced engineering and strategic positioning are defining the next generation of ADCs.
European biotech leaders say optimism is returning
A survey of senior figures in European biopharma companies has found that dealmaking and M&A are expected to increase, with some suggesting that this will be helped by policy uncertainties in the US.
Capital, partnering, and AI take center stage for biopharma leads
Three-quarters of biopharma executives expect partnering and M&A appetite to increase over the next 12 months, according to the BIO-Europe Biopharma C-Suite Agenda Survey.
Rethinking biotech investment and innovation in a productivity-driven era
M Ventures' Hakan Goker discusses navigating an era where speed, data depth, and commercial pragmatism define success.
Winning in biopharma: Strategic dealmaking and commercialization essentials
Breakthrough science alone won't win in biopharma - execution, partnerships and global strategy decide who commercializes.
Why BIO-Europe 2026 matters: The evolution of strategic biopharma collaboration
2026 marks a significant evolution for BIO-Europe. Whilst long recognised as Europe's largest partnering conference, it's now expanding to become the continent's most important biopharma strategy forum – where the industry's agenda is genuinely set, not just discussed.
Biopharma's selective recovery: Differentiation and strategic clarity define success
Mary Clark, CEO of Optimum Strategic Communications, discusses how capital, partnering and M&A now concentrate around credible execution and strategic relevance.
Biopharma Vital Signs – Part 4: The New Partnership Playbook
Informa Connect's Claire Macht shares her insights in The Medicine Maker on the transformation of biopharma partnerships—where strategic collaboration and integration are replacing traditional supplier relationships to meet the industry's evolving challenges.
Jeremy Levin's message to Europe: This is your moment – if you choose to act
As America's biotech ecosystem faces unprecedented structural challenges, industry expert Jeremy Levin sees a historic opportunity for Europe to claim leadership in life sciences innovation.
[Podcast] How BIO-Europe is expanding beyond dealmaking in 2026
The life sciences industry has always had one great meeting place, a few days in November where the deals get done, the partnerships form, and the direction of the industry quietly shifts. For more than three decades, that place has been BIO-Europe.
Bio-Europe unveils renewed vision as global biopharma strategy forum
Bio-Europe is repositioning its annual conference to expand beyond its traditional partnering focus into what organisers describe as a broader biopharma strategy forum, aiming to bring together senior decision-makers across pharma, biotech and investment.
BioXconomy: The silver lining in Europe's biopharma storm
European biopharma faces an existential moment: adapt to new global realities or risk losing its innovation leadership.
BIO-Europe partnering: Australian biotech companies share their experiences
Over three days, more than 32,000 meetings were facilitated between biotechs, pharma, venture capital, and industry service providers, with participants from more than 60 countries taking full advantage of their time in the Austrian capital to renew existing contacts and forge new ones.
BIO-Europe: How Europe’s Biopharma Industry Must Respond To Rising Threats
There will be no return to normal for the European biopharma sector which needs to turn increasing macro-pressures into opportunities and become leaner and more efficient, experts at BIO-Europe said this week.
BIO-Europe 2025 to Spotlight Biopharma Innovation and Deal-Making in Vienna
BIO-Europe 2025 in Vienna will gather global biopharma leaders to explore investment, manufacturing, and rare disease innovation.